What is effective half-life?

Effective half-life is the time for the activity of a radiopharmaceutical in a given organ or in the whole body to fall to half its value, accounting for both physical radioactive decay and biological clearance. It is always shorter than either the physical half-life or the biological half-life alone.

How is effective half-life calculated?

The effective decay constant is the sum of the physical and biological decay constants, so one over the effective half-life equals one over the physical half-life plus one over the biological half-life. Equivalently, the effective half-life equals the product of the two half-lives divided by their sum.

Why does effective half-life matter for absorbed dose?

Absorbed dose is proportional to the time-integrated activity in the source region. For a mono-exponential clearance, that integral equals the initial activity divided by the effective decay constant, so a longer effective half-life means more cumulated activity and a higher absorbed dose.

Is effective half-life the same for every organ and patient?

No. The physical half-life is a fixed nuclear property, but the biological half-life depends on the organ, the radiopharmaceutical, and patient physiology such as renal function. Effective half-life therefore varies by organ and between patients, which is why measured dosimetry can differ from population averages.

How is effective half-life measured in the clinic?

It is estimated by acquiring serial measurements of activity over time in an organ or the whole body, fitting a time-activity curve, and extracting the clearance rate. Adequate sampling and correct timing are essential because a poorly sampled curve can bias the effective half-life and the resulting dose estimate.

Does effective half-life affect radiation safety and patient release?

Yes. Retained activity, the effective clearance rate, and the resulting dose rate to others inform patient-release calculations after radiopharmaceutical therapy, so effective half-life is relevant to both dosimetry and radiation protection planning.

Effective Half-Life in Nuclear Medicine Dosimetry

Effective half-life is the quantity that ties a radiopharmaceutical's fixed physical decay to the patient-specific biology that clears it from the body. Because absorbed dose depends on how much activity accumulates in a source region over time, and that time-integrated activity is governed by the effective half-life, this one number frequently controls the dose an organ receives — in diagnostic imaging and, most consequentially, in radiopharmaceutical therapy.¹²

Understanding effective half-life is therefore foundational to internal dosimetry. It explains why two patients receiving the same administered activity can receive very different organ doses, why timing of imaging or bioassay matters, and why measured dosimetry can diverge from textbook population estimates.¹³

Introduction

Effective half-life is shorter than either the physical half-life or the biological half-life, because two independent removal processes act at the same time. Radioactive decay removes activity at a rate set by the radionuclide alone, while biological clearance — urinary excretion, hepatobiliary transit, and turnover in tissue — removes it at a rate set by the radiopharmaceutical and the patient. The combined, observed clearance is faster than either process by itself.¹

For a diagnostic tracer such as fluorine-18 fluorodeoxyglucose, the physical half-life is short and often dominates the observed clearance. For a therapy radionuclide such as lutetium-177 or iodine-131, physical and biological clearance can be comparable, so both must be measured to estimate organ dose accurately.³⁴⁵

This article develops the effective half-life from first principles, works through the governing equations with numeric examples, connects it to the MIRD time-integrated activity that drives absorbed dose, and reviews the clinical and regulatory context in which nuclear medicine physicists apply it.

Topic Explanation

Three half-lives, one observation

Three related quantities describe how activity leaves an organ or the whole body:

Physical half-life ( $T_{p}$ ) — the time for radioactive decay alone to reduce the number of radioactive atoms by half. It is a fixed property of the radionuclide and is independent of chemical form, temperature, or biology.⁶
Biological half-life ( $T_{b}$ ) — the time for biological processes alone to remove half of an administered substance from an organ or the body, in the absence of decay. It depends on the radiopharmaceutical, the organ, and patient physiology.
Effective half-life ( $T_{e}$ ) — the time for the measured activity to fall to half, with decay and biological clearance acting together. This is what an external detector or a bioassay actually observes.

Because both processes remove activity, they add as rates. The effective clearance is always faster, so the effective half-life is always the shortest of the three.¹

Why the effective half-life, not the physical half-life, sets the dose

A common misconception is that a long physical half-life automatically means a high organ dose. What matters for absorbed dose is not the physical half-life but the residence of activity in the source region — how much activity is present and for how long. If a radiopharmaceutical is excreted quickly, its activity leaves the organ long before it decays, and the dose is limited by biology, not physics.¹²

This is precisely why effective half-life is the operative quantity. It captures the actual time-course of activity in the tissue, blending the unavoidable physical decay with the modifiable, patient-specific biological clearance. Two organs exposed to the same initial activity of the same radionuclide can receive different doses if their biological clearance rates differ.³⁷

Key Technical Principles

The governing equations

Radioactive decay is a first-order process with decay constant $λ = ln 2/ T$ . Because physical decay and biological clearance are independent first-order removal processes, their decay constants add:

λ_{e} = λ_{p} + λ_{b}

Substituting $λ = ln 2/ T$ for each term and dividing through by $ln 2$ gives the reciprocal relationship most physicists memorize:

\frac{1}{T _{e}} = \frac{1}{T _{p}} + \frac{1}{T _{b}}

Solving for the effective half-life yields the equivalent product-over-sum form:

T_{e} = \frac{T _{p} \cdot T _{b}}{T _{p} + T _{b}}

Two limiting cases are worth internalizing. When biological clearance is very slow ( $T_{b} ≫ T_{p}$ ), the effective half-life approaches the physical half-life, and physics controls the dose. When biological clearance is very fast ( $T_{b} ≪ T_{p}$ ), the effective half-life approaches the biological half-life, and physiology controls the dose.¹

Physical half-lives of common radionuclides

The physical half-life is the fixed input to every effective half-life calculation. The following values are the standard evaluated nuclear data for radionuclides used across diagnostic and therapeutic nuclear medicine.⁶

Radionuclide	Physical half-life ( $T_{p}$ )	Principal emission	Representative use
Fluorine-18	109.8 min (1.83 h)	β⁺	FDG and other PET tracers
Technetium-99m	6.01 h	γ (140 keV)	General SPECT imaging
Iodine-123	13.2 h	γ (159 keV)	Thyroid and neuroendocrine imaging
Iodine-131	8.02 d	β⁻, γ	Thyroid ablation and therapy
Lutetium-177	6.647 d	β⁻, γ	PRRT and PSMA radioligand therapy
Yttrium-90	2.67 d (64.1 h)	β⁻	Radioembolization, radioimmunotherapy
Radium-223	11.4 d	α	Bone-metastatic prostate cancer

Note that lutetium-177 in the ground state (about 6.6 days) is distinct from the long-lived metastable impurity lutetium-177m, a difference that matters for waste handling and purity but not for the effective half-life of the ground-state therapy activity.⁶

From effective half-life to time-integrated activity

Absorbed dose in the MIRD schema is the product of the time-integrated activity (also called cumulated activity, $\tilde{A}$ ) in a source region and the dose factor, or S value, linking that source to the target.¹² The effective half-life enters through the time integral of the activity.

For an organ whose activity follows a single decaying exponential after an initial uptake $A_{0}$ , the activity at time $t$ is $A (t) = A_{0} e^{- λ_{e} t}$ , and its time integral from zero to infinity is:

\tilde{A} = \int_{0}^{\infty} A_{0} e^{- λ_{e} t} d t = \frac{A _{0}}{λ _{e}} = 1.443 A_{0} T_{e}

The factor 1.443 is simply $1/ ln 2$ . The equation makes the dependence explicit: for a fixed uptake, the cumulated activity — and therefore the absorbed dose — scales directly with the effective half-life. Doubling the effective half-life doubles the cumulated activity and, all else equal, doubles the dose from that source region.¹²

Real time-activity curves are often multi-exponential, with a fast washout phase followed by a slower retention phase, so clinical dosimetry fits several components and integrates each. But the single-exponential result captures the essential physics and is the workhorse for hand calculations and quality checks.⁸⁹

Worked example: iodine-131 in the thyroid

Consider iodine-131 with a physical half-life $T_{p} = 8.02$ days. Suppose serial measurements in a patient's thyroid remnant are consistent with a biological half-life $T_{b} = 20$ days (an illustrative value chosen to demonstrate the arithmetic; the true biological clearance must always be measured per patient). The effective half-life is:

T_{e} = \frac{8.02 \times 20}{8.02 + 20} = \frac{160.4}{28.02} \approx 5.72 days

The effective half-life, 5.72 days, is shorter than both inputs, as expected. If the initial uptake in the remnant is $A_{0} = 40$ MBq, the time-integrated activity is:

\tilde{A} = 1.443 \times 40 MBq \times 5.72 d \approx 330 MBq \cdot d

Had the biological clearance been faster — say $T_{b} = 5$ days — the effective half-life would drop to about 3.08 days and the cumulated activity to roughly 178 MBq·d, nearly a factor of two lower for the same uptake. This sensitivity is why measuring, rather than assuming, the biological component is central to defensible therapy dosimetry.⁵⁸

Worked example: whole-body clearance and patient safety

The same mathematics governs whole-body retention, which drives dose to others and patient-release decisions. If a therapy radionuclide is retained with an effective half-life of, say, 0.7 days early after administration (a fast urinary washout phase) transitioning to a slower phase, the early effective clearance is dominated by biology, while later retention approaches the physical decay rate. Because dose rate to bystanders tracks retained activity, the effective clearance rate — not the physical half-life alone — determines how quickly external dose rates fall.¹⁷

When one exponential is not enough

Real time-activity curves for many radiopharmaceuticals are not single exponentials. A typical therapy agent shows a fast early washout phase — often dominated by urinary excretion of unbound activity — followed by a slower retention phase governed by receptor binding and tissue turnover. Each phase has its own effective half-life, and the cumulated activity is the sum of the integrals of all phases.⁸ Studies of lutetium-177 peptide receptor therapy have reported distinct fast and slow effective half-lives in the kidney, spleen, and marrow, and have shown that the estimated organ dose is sensitive to how well the early phase is captured.⁷⁸ The practical implication is that the number of time points and their placement are not incidental details: omitting the early phase can bias the fitted effective half-life and the resulting dose, which is why simplified sampling schemes must be validated against fuller ones before they are trusted for clinical dosimetry.⁸

Clinical Impact

Effective half-life is where population dose estimates give way to personalized dosimetry. Diagnostic dose coefficients, such as those compiled by the ICRP for commonly used radiopharmaceuticals, are built on standardized biokinetic models with representative biological half-lives. They are appropriate for prospective risk estimates and justification, but they are averages.¹⁰

In radiopharmaceutical therapy, the stakes are higher and the biology more variable. For peptide receptor radionuclide therapy with lutetium-177 DOTATATE, the kidneys and bone marrow are organs at risk, and their effective half-lives can vary substantially between patients because renal clearance and receptor binding differ.³⁷ For lutetium-177 PSMA radioligand therapy, salivary glands, kidneys, and marrow are the dose-limiting tissues, and serial SPECT/CT quantification is used to reconstruct patient-specific time-activity curves and effective half-lives.⁴

For iodine-131, the effective half-life in a thyroid remnant or in benign hyperthyroid tissue is a direct determinant of delivered dose, and studies have shown that pre-therapy and post-therapy effective half-lives can differ, which affects how a prescribed activity translates into absorbed dose.⁵¹¹¹² The practical consequence is that a fixed administered activity does not guarantee a fixed absorbed dose; the effective half-life is one of the reasons why.

Practical Optimization Tips

Sample the time-activity curve deliberately

The effective half-life is only as good as the time-activity curve behind it. Too few time points, or points clustered at the wrong times, can bias the fitted clearance rate and propagate directly into the dose estimate.⁸⁹ Sampling should bracket both the fast and slow clearance phases relevant to the radiopharmaceutical.

Acquire an early point near peak uptake to anchor $A_{0}$ .
Acquire later points spaced to characterize the dominant washout phase.
Match the total observation window to the effective half-life, not the physical half-life alone.

Distinguish organ and whole-body effective half-lives

The effective half-life of the whole body is generally not the same as the effective half-life of a specific organ, because biological clearance differs by tissue. Report and apply them separately, and be explicit about which one a given calculation uses.¹³

Use the single-exponential result as a sanity check

Even when clinical software fits multi-exponential curves, the relationship $\tilde{A} = 1.443 A_{0} T_{e}$ is a fast independent check on the order of magnitude of the cumulated activity. A result that disagrees by a large factor signals a fitting or units error worth investigating before it reaches a dose report.²

Remember the limiting behavior

When a quick estimate is needed, recall that the effective half-life is dominated by whichever process is faster. For short-lived radionuclides with slow biology, $T_{e} \approx T_{p}$ ; for long-lived radionuclides with fast excretion, $T_{e} \approx T_{b}$ . This lets a physicist bound a calculation before doing the full arithmetic.¹

Regulatory Considerations

Effective half-life underlies both dose estimation and radiation protection, so it touches several parts of the medical-use framework. In the United States, the medical use of byproduct material is governed by 10 CFR Part 35, and the associated radiation protection requirements and dose limits appear in 10 CFR Part 20, administered by the U.S. Nuclear Regulatory Commission or an Agreement State program.¹³¹⁴

Dosimetry methodology. The MIRD schema, standardized in MIRD Pamphlet No. 21, defines the time-integrated activity and dose factors that turn measured effective half-lives into absorbed doses; MIRD Pamphlet No. 16 addresses the quantitative biodistribution measurements from which effective half-lives are derived.¹²
Diagnostic dose coefficients. ICRP Publication 128 compiles biokinetic models and dose coefficients for frequently used diagnostic radiopharmaceuticals, providing the population-average biological behavior against which patient-specific effective half-lives can be compared.¹⁰
Patient release. After radiopharmaceutical therapy, release of the patient is evaluated against dose limits to other individuals. Retained activity and its effective clearance rate feed those calculations, connecting effective half-life directly to radiation safety planning.⁷

Jurisdiction matters in practice: NRC regulations govern byproduct material such as lutetium-177 and iodine-131, while Agreement States administer parallel programs. DRPS supports facilities across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware, where the specific administering authority varies but the underlying dosimetry physics does not. Always confirm requirements with the authority having jurisdiction.

Frequently Asked Questions (FAQs)

Is the effective half-life always shorter than the physical half-life?

Yes. Because biological clearance and physical decay both remove activity, the combined effective clearance is faster than either alone, so the effective half-life is shorter than both the physical and the biological half-life.¹

Can the biological half-life be measured directly?

The biological half-life is usually inferred, not measured directly. Physicists measure the effective clearance from serial activity data, then subtract the known physical decay constant to isolate the biological component, since the decay constants add.¹⁸

Why do two patients with the same injected activity get different doses?

The physical half-life is identical for both, but biological clearance depends on organ function and physiology. Differences in the biological half-life change the effective half-life, the time-integrated activity, and therefore the absorbed dose.³⁷

Does effective half-life apply to diagnostic tracers too?

Yes, though for short-lived tracers such as fluorine-18 the physical half-life often dominates. The concept still governs how long activity resides in tissue and is used in diagnostic dose coefficient models.¹⁰

Key Takeaways

Effective half-life combines physical decay and biological clearance and is always the shortest of the three half-lives.¹
The reciprocals add: one over the effective half-life equals one over the physical half-life plus one over the biological half-life.
Absorbed dose scales with time-integrated activity, which for single-exponential clearance equals $1.443 A_{0} T_{e}$ — so a longer effective half-life means a higher dose.²
Physical half-life is a fixed nuclear property; biological and effective half-lives vary by organ and patient.³
Personalized therapy dosimetry for lutetium-177 and iodine-131 depends on measuring the effective half-life, because a fixed administered activity does not guarantee a fixed absorbed dose.⁴⁵
Careful time-activity sampling is essential; a poorly sampled curve biases the effective half-life and the dose estimate.⁸

Conclusion

Effective half-life is a small equation with outsized consequences. By merging the fixed physics of radioactive decay with the variable biology of clearance, it determines the time-integrated activity that drives absorbed dose in both imaging and therapy. A nuclear medicine physicist who understands where the effective half-life comes from — and how sensitive the resulting dose is to it — is equipped to design better time-activity sampling, produce defensible dose estimates, and explain why measured, patient-specific dosimetry matters. As radiopharmaceutical therapy continues to expand, effective half-life remains one of the most practical and consequential quantities in internal dosimetry.¹²³

How DRPS Can Help

Diagnostic Radiation Physics Services (DRPS) supports nuclear medicine and theranostics programs across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware with PET/CT and nuclear medicine physics, internal dosimetry support, quantitative imaging workflows, and medical physicist consulting performed by board-certified medical physicists.

A dosimetry program built on correctly measured effective half-lives — not assumed averages — is the difference between reporting a number and reporting a defensible absorbed dose.

Related Resources

References

Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD Pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry—standardization of nomenclature. J Nucl Med. 2009;50(3):477-484. doi:10.2967/jnumed.108.056036. doi.org
Siegel JA, Thomas SR, Stubbs JB, et al. MIRD Pamphlet No. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40(2):37S-61S. pubmed.ncbi.nlm.nih.gov
Marin G, Vanderlinden B, Karfis I, et al. A dosimetry procedure for organs-at-risk in 177Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours. Phys Med. 2018;56:41-49. doi:10.1016/j.ejmp.2018.11.001. doi.org
Zang J, Fan X, Wang H, et al. First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46(1):148-158. doi:10.1007/s00259-018-4096-y. doi.org
Kumar P, Bal C, Damle NA, et al. Lesion-wise comparison of pre-therapy and post-therapy effective half-life of iodine-131 in pediatric and young adult patients with differentiated thyroid cancer undergoing radioiodine therapy. Nucl Med Mol Imaging. 2019;53(3):199-207. doi:10.1007/s13139-019-00592-z. doi.org
National Nuclear Data Center, Brookhaven National Laboratory. NuDat: evaluated nuclear structure and decay data. nndc.bnl.gov
Delker A, Ilhan H, Zach C, et al. The influence of early measurements onto the estimated kidney dose in [177Lu][DOTA0,Tyr3]octreotate peptide receptor radiotherapy of neuroendocrine tumors. Mol Imaging Biol. 2015;17(5):726-734. doi:10.1007/s11307-015-0839-3. doi.org
Zhao W, Esquinas PL, Frezza A, et al. Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: a 177Lu-DOTATATE patient study. Phys Med Biol. 2019;64(17):175006. doi:10.1088/1361-6560/ab3039. doi.org
Merrill S, Horowitz J, Traino AC, et al. Accuracy and optimal timing of activity measurements in estimating the absorbed dose of radioiodine in the treatment of Graves' disease. Phys Med Biol. 2011;56(3):557-571. doi:10.1088/0031-9155/56/3/003. doi.org
International Commission on Radiological Protection. ICRP Publication 128: radiation dose to patients from radiopharmaceuticals—a compendium of current information related to frequently used substances. Ann ICRP. 2015;44(2 Suppl):7-321. icrp.org
Abuqbeitah M, Sağer S, Demir M, et al. The impact of different computational assumptions in 131I dosimetry for hyperthyroidism therapy. Med Phys. 2020;47(11):5810-5816. doi:10.1002/mp.14478. doi.org
Oliveira CV, Camozzato TSC, Dorow PF, Pasqueta J. Analysis of residence time, effective half-life, and internal dosimetry before radioiodine therapy. J Nucl Med Technol. 2022;50(3):233-239. doi:10.2967/jnmt.121.263502. doi.org
U.S. Nuclear Regulatory Commission. 10 CFR Part 35, Medical Use of Byproduct Material. nrc.gov
U.S. Nuclear Regulatory Commission. 10 CFR Part 20, Standards for Protection Against Radiation. nrc.gov